Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.55 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | CTSV | O60911 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1150828 | 1.00 | KLK7 (0.55) | KLK7STSAGTR2GPR119MEN1 | |
| SCHEMBL16732580 | 1.00 | KLK7 (0.55) | KLK7STSAGTR2GPR119MEN1 | |
| SCHEMBL7698816 | 1.00 | KLK7 (0.55) | KLK7STSAGTR2GPR119MEN1 | |
| SCHEMBL20444437 | 0.92 | KLK7 (0.57) | KLK7STSAGTR2MEN1KMT2A | |
| SCHEMBL10035703 | 0.91 | KLK7 (0.53) | KLK7STSGPR119MEN1KMT2A | |
| SCHEMBL16943520 | 0.90 | KLK7 (0.57) | KLK7STSGPR119MEN1KMT2A | |
| SCHEMBL16943519 | 0.90 | KLK7 (0.57) | KLK7STSGPR119MEN1KMT2A | |
| SCHEMBL21996541 | 0.90 | KLK7 (0.57) | KLK7STSGPR119MEN1KMT2A | |
| SCHEMBL2984486 | 0.87 | KLK7 (0.56) | KLK7STSGPR119MEN1KMT2A | |
| SCHEMBL21996511 | 0.86 | KLK7 (0.57) | KLK7STSGPR119MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758480-B2 | 1-(cycloalkyl-carbonyl)proline derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-9758480-B2 | 1-(cycloalkyl-carbonyl)proline derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-20150210640-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20150210640-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| EP-2876105-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2015-05-27 | — | — | EP | disclosed |
| EP-1166781-A1 | PROTEASOME INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001010837-A1 | MULTIVALENT SULFONAMIDES | THE PROCTER & GAMBLE COMPANY (US) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210640-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | RB1, F2, SFPQ | KLK7 3487/4885STS 3255/4885AGTR2 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.